Abstract: Objective : To Evaluated therapeutic effect and toxicity handronate for patients withcancer and lytic bone metastases. Methods : 7 patients with hypercalcemia were treated with Ihan-dronate; 50 patients were randomized to the arm A (Ibandronate group) and reived Ihandronate 4mg;40 patients were randomized to the arm B(pamidronate group) and reived pamidronate 90mg. Results :Response rate were 100% in 5 evaluated patients with hypercalcemia. Response rate of bone pain were73.5% in A group and 59.0% in B group (P>0.05). Toxicity including mild fever ,nausea, vomiting,myalgia. Conclusion : Ihandronate can decrease serum calcium and relive bone pain ,similar to pamidronate.